OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
24 jan 2012 - 21:29
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces the proposal to appoint Staf van Reet to the Supervisory Board
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces today that the Supervisory Board of the Company plans to propose Dr. Staf Van Reet as chairman of the Supervisory Board at the next General Meeting of Shareholders in May. This appointment will be for a period of four years.
Dr. Van Reet has a long track record of successes in the pharma and biotech industry. He served among others as the Managing Director of Janssen Pharmaceutica N.V. and President of the Janssen Research Foundation, supervising the worldwide research and development activities of the Janssen Pharmaceutica Group (part of the J&J Group of Companies). Staf also gained extensive experience in the biotech sector as co-founder of Movetis and Chairman of their Board of Directors until the acquisition of the company by Shire. Currently, he is still active in various areas of the life sciences, among others as Chairman of the Board of Actogenix and Okapi Sciences and as a regular Board member of Thrombogenics, Biocartis, TheraSolve and the VIB, the Flemish Institute of Biotechnology.
The Supervisory Board also announces that Dr. de Ruiter has informed the Board of her decision to resign from the Supervisory Board as of January 25.
Datum laatste update: 10 januari 2026